Document: Applications for new human medicines under evaluation: August 2025-2025/8/7

Page: Vaccine Monitoring Platform-2025/8/7

Document: Vaccine Monitoring Platform: List of EMA-funded studies-2025/8/7

Document: Medicine shortage communication (MSC): Zypadhera (olanzapine pamoate monohydrate <210 mg / 300 mg / 405 mg> powder and solvent for prolonged release suspension for injection)-2024/8/7

Document: Agenda - Multi-stakeholder workshop on tailored clinical approach for biosimilars-2025/8/7

Document: Ketoprofen: European public maximum-residue-limit assessment report (EPMAR) - CVMP-2025/8/6

Page: Quality guidelines-2025/8/6

Document: Feedback from European Medicine Agency (EMA) to the EU Commission request to evaluate the feasibility of alternatives to replace titanium dioxide (TiO2) in medicinal products and its possible impact on medicines’ availability-2025/8/6

Document: Annex I - Use of titanium dioxide as excipient in human and veterinary medicines and identification of alternatives - Industry feedback to QWP experts / EMA questions - Final report February 2024-2025/8/6

Page: Clinical investigation of medicines for the treatment of Alzheimer's disease - Scientific guideline-2025/8/6